Key result
AST-120 treatment in CHF patients with moderate CKD significantly reduced the length of hospital stay from 39.7 to 4.14 days and admissions from 0.79 to 0.21 over 24 months.
Why the study?
Does AST-120 improve cardiorenal function and reduce hospitalizations in patients with chronic heart failure and moderate CKD?
Cohort (n=20)
Does AST-120 improve cardiorenal function and reduce hospitalizations in patients with chronic heart failure and moderate CKD?
Absolute Event Rate: 4.14% vs 39.7%
AST-120 may improve cardiorenal function in CHF with moderate CKD; leaves open whether randomized trials confirm benefit.
BACKGROUND: The detailed mechanisms and treatment methods of chronic kidney disease (CKD) in patients with chronic heart failure (CHF) are not fully understood. We conducted a prospective study in CHF patients manifesting CKD to examine if AST-120 (Kremezin) improves cardiac and renal functions. METHODS: Twenty outpatients with CHF manifesting moderate CKD (serum creatinine 1.3-2.0 mg/dL) were studied. The patients had received AST-120 at a dosage of 6 g/day in combination with existing medications for 24 months. Some parameters of kidney and heart function were monitored. Also the cumulative length of hospital stay and number of admissions for the 2-year periods before and after initiation of AST-120 treatment were calculated. RESULTS: Results of renal function tests, atrial natriuretic peptide, edema, cardiothoracic ratio and hospital stay indicated significant improvements in patients treated with AST-120. The length of hospital stay and number of admissions both decreased significantly during the 2 years of AST-120 treatment compared with the 2 years before treatment, from 39.7 ± 12.9 days to 4.14 ± 2.5 days, and from 0.79 ± 0.21 admissions to 0.21 ± 0.11 admissions, respectively. CONCLUSIONS: AST-120 contributes to the improvement of cardiac and renal functions, and consequently improves the quality of life of patients.
No takes yet. Share an insight, caveat, or question.
Shibahara et al. (2010) conducted a cohort in chronic heart failure with moderate chronic kidney disease (n=20). AST-120 (Kremezin) vs. 2-year period before treatment was evaluated on length of hospital stay (days). AST-120 treatment in CHF patients with moderate CKD significantly reduced the length of hospital stay from 39.7 to 4.14 days and admissions from 0.79 to 0.21 over 24 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: